within Pharmacolibrary.Drugs.ATC.J;

model J01GB10
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0015,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01GB10</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ribostamycin is an aminoglycoside antibiotic, primarily used for the treatment of infections caused by Gram-negative bacteria. It has historically been used for severe bacterial infections but is not widely used or approved in current clinical practice due to the availability of newer, less toxic antibiotics.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult with normal renal function based on class similarity to other aminoglycosides, due to absence of direct ribostamycin PK publications.</p><h4>References</h4><ol><li><p>Yamasaku, F, et al., &amp; Umemura, K (1980). Pharmacokinetics of ribostamycin in healthy volunteers and patients with impaired renal function. <i>The Japanese journal of antibiotics</i> 33(12) 1318–1331. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7241802/&quot;>https://pubmed.ncbi.nlm.nih.gov/7241802</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01GB10;
